NF1 and neurofibromatosis type 1: Further in vivo studies may determine whether systemic administration of AAV-GRDC24 can rescue differentiating Schwann cell precursors with complete somatic NF1 inactivation in NF1 patients during neurofibroma formation, potentially preventing future tumors and treating existing ones.